LSX-Blog.png

Something Powerful

Tell The Reader More

The headline and subheader tells us what you're offering, and the form header closes the deal. Over here you can explain why your offer is so great it's worth filling out a form for.

Remember:

  • Bullets are great
  • For spelling out benefits and
  • Turning visitors into leads.

Artios Pharma’s £65m Series B to spur development ...

Key findings:

Read More

Dyadic International: Working to change the game i...

Key learnings:

Read More

What life sciences companies need to know about pr...

Pre-approval access is evolving at a rapid pace. Mark Corbett (pictured), E...

Read More

Evox Therapeutics raises £35.5m Series B to advanc...

Key learnings: UK biotech Evox Therapeutics recently announced its £35.5 mi...

Read More

Commercialise and partner successfully in Europe a...

Understand how to commercialise via partnering in Europe and other markets ...

Read More

Examining AI's potential in healthcare

Artificial Intelligence (AI) systems hold great potential in taking on an i...

Read More

Enhancing your drug development journey

Experience drug development – designed around you®

Read More

John Ratliff introduces the LSX C-Suite Challenges...

Heraclitus, the Greek philosopher, who said: “change is the only constant i...

Read More

C-suite survey uncovers life sciences challenges

For more than three-quarters (78%) of C-level respondents in the life scien...

Read More

Interview with Avacta Group's Alastair Smith

In this video, Donald Leggatt, Head of Investor Relations at London South E...

Read More

Biotech and Money rebrands to reflect wider life s...

Biotech and Money is now LSX – The network for life science executive leade...

Read More

Growing opportunities in cannabinoid-based treatme...

In June 2018 it was announced that venture capital firm Casa Verde Capital,...

Read More

Add Your Response